Rigel Pharmaceuticals reported first-quarter 2026 earnings of $0.44 per share and a total profit of $8.7 million [1, 7].
The results highlight a period of growth in product sales for the South San Francisco company, though profitability fell short of some market expectations.
Total revenues for the quarter ended March 2026 reached $58.8 million [4]. This total includes $54.9 million in net product sales and $3.9 million in contract revenues derived from collaborations [5, 6]. The company said that net product sales grew by 26% compared to the previous year [8].
Despite the sales growth, the earnings per share of $0.44 [1] did not meet the Zacks consensus estimate of $0.74 [2]. This figure also represents a decrease from the $0.63 per share reported one year ago [3].
Company leadership discussed these financial outcomes and the evolution of the company's portfolio during an earnings call held on May 5 [9, 10]. The session focused on strategic execution and the company's current trajectory in the pharmaceutical market [11, 12].
Rigel continues to manage its portfolio from its California headquarters as it balances product expansion with the costs of strategic execution [13].
“Net product sales grew by 26% compared to the previous year.”
The divergence between Rigel's strong top-line product sales growth and its failure to meet earnings-per-share estimates suggests a period of increased operational costs or strategic investment. While the 26% growth in product sales indicates healthy market demand, the decline in per-share earnings compared to the previous year may signal pressure on margins as the company evolves its portfolio.
